A process for preparing 11-deoxyprostaglandin E.sub.1, E.sub.2 and E.sub.3 and analogs thereof is realized by treating an appropriate di(lower)alkyl 3-(optionally substituted)-2-formylcyclopropane-1,1-dicarboxylate with an ylid prepared from a Wittig reagent of formula (AlkO).sub.2 POCH.sub.2 CO-(c)-CH.sub.3 in which Alk is an alkyl containing one to three carbon atoms and (c) is either (CH.sub.2).sub.q wherein q is an integer from 1 to 6 or cis CH.sub.2 CH.dbd.CH(CH.sub.2).sub.r wherein r is an integer from 0 to 3 to obtain the corresponding compound of formula: ##STR1## in which R.sup.2 is hydrogen, lower akyl or CH.sub.2 OR.sup.3 wherein R.sup.3 is lower alkanoyl, R.sup.4 is lower alkyl and (c) is as defined herein. The latter compound is reduced with an alkali metal borohydride to yield the corresponding alcohol derivative. Condensation of this alcohol derivative or preferably its corresponding tetrahydropyran-2-yl ether derivative with a triester of formula CH(COOR.sup.6).sub.2 -(a)-(CH.sub.2)pCOOR in which R and R.sup.6 are lower alkyl, (a) is CH.sub.2 CH.sub.2, cis CH.dbd.CH or C.tbd.C and p is an integer from 2 to 4, gives the corresponding cyclopentanonetriester of formula ##STR2## in which (a), (c), p, R, R.sup.4 and R.sup.6 are as defined herein, R.sup.5 is hydrogen or tetrahydropyran-2-yl, respectively, and R.sup.7 is hydrogen or lower alkyl; the lactonized form of the cyclopentanone-triester being obtained from said alcohol derivative in which R.sup.2 is CH.sub.2 OR.sup.3 wherein R.sup.3 is lower alkanoyl. In the instance when R.sup.5 is tetrahydropyran-2-yl the cyclopentanonetriester is treated with an acid to give the corresponding compound in which R.sup.5 is hydrogen. The instant compound is then treated with a base under aqueous conditions, followed by optional esterification and acylation to give the desired 11-deoxyprostaglandin derivatives of formula ##STR3## in which (a), (c) and p, are as defined herein, (b) is trans CH.dbd.CH, R is hydrogen or lower alkyl, R.sup.1 is hydrogen or lower alkanoyl and R.sup.2 is hydrogen, lower alkyl or CH.sub.2 OR.sup.3 wherein R.sup.3 is hydrogen or lower alkanoyl. The derivatives possess prostaglandin-like biological activity and method for their use are given.
本发明涉及一种制备11-去氧
前列腺素E.sub.1,E.sub.2和E.sub.3及其类似物的过程,通过将适当的二(低)烷基3-(可选取取代基)-2-甲酰基
环丙烷-1,1-二
羧酸酯与由Wittig试剂制备的ylid反应,所述Wittig试剂的
化学式为(AlkO).sub.2 POCH.sub.2 CO-(c)-CH.sub.3,其中Alk是含有1至3个碳原子的烷基,(c)是(CH.sub.2).sub.q,其中q是1至6的整数,或者是顺式CH.sub.2 CH.dbd.CH(CH.sub.2).sub.r,其中r是0至3的整数,以获得相应的化合物的式子:##STR1## 其中R.sup.2是氢、低烷基或CH.sub.2 OR.sup.3,其中R.sup.3是低脂肪酰基,R.sup.4是低烷基,(c)如上所定义。后者的化合物经过碱
金属
硼氢化物还原后,得到相应的醇衍
生物。将该醇衍
生物或者更好的是其相应的
四氢吡喃-2-基醚衍
生物与
化学式为CH(COOR.sup.6).sub.2-(a)-(CH.sub.2)pCOOR的三酯缩合,其中R和R.sup.6是低烷基,(a)是CH.sub.2 CH.sub.2,顺式CH.dbd.CH或C.tbd.C,p是2至4的整数,得到相应的
环戊酮三酯的
化学式:##STR2## 其中(a),(c),p,R,R.sup.4和R.sup.6如上所定义,R.sup.5分别为氢或
四氢吡喃-2-基,R.sup.7为氢或低烷基;从所述醇衍
生物中获得
环戊酮三酯的内酯形式,其中R.sup.2为CH.sub.2 OR.sup.3,其中R.sup.3为低脂肪酰基。在R.sup.5为
四氢吡喃-2-基时,将
环戊酮三酯处理成R.sup.5为氢的相应化合物。然后在
水溶液条件下将瞬时化合物处理成碱,随后进行可选的酯化和酰化,以得到所需的
化学式为:##STR3## 其中(a),(c)和p如上所定义,(b)为顺式CH.dbd.CH,R为氢或低烷基,R.sup.1为氢或低脂肪酰基,R.sup.2为氢、低烷基或CH.sub.2 OR.sup.3,其中R.sup.3为氢或低脂肪酰基的11-去氧
前列腺素衍
生物。这些衍
生物具有类似
前列腺素的
生物活性,并给出了它们的使用方法。